Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP-HRMB phase III trial for high-risk medulloblastoma
ISRCTN16314648Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Jan 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of carboplatin, etoposide, thiotepa, temozolomide, cisplatin and 3 more in medulloblastoma (5 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Jan 2021; status: recruiting.
02
Drugs
carboplatinetoposidethiotepatemozolomidecisplatin
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on ISRCTN16314648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16314648.